Klotho, a Protective Renal Factor for Platelet Lifespan
Jun Peng
DOI: https://doi.org/10.1111/jth.15886
2022-01-01
Journal of Thrombosis and Haemostasis
Abstract:Chronic kidney disease (CKD) is a progressive condition characterized by kidney damage or reduced kidney function and is categorized into five stages based on the Kidney Disease Outcomes Quality Initiative guidelines. Owing to the lack of an effective cure and high morbidity and mortality in the general adult population, CKD will become the fifth leading cause of death globally by 2040.1.Kalantar‐Zadeh K. Jafar T.H. Nitsch D. Neuen B.L. Perkovic V. Chronic kidney disease.Lancet. 2021; 398: 786-802Abstract Full Text Full Text PDF PubMed Scopus (189) Google Scholar Usually, CKD is considered a hypercoagulable state associated with a high prevalence of arterial and venous thromboembolisms, which have become the main causes of mortality in these patients. However, hemostasis and thrombosis remain controversial in patients with CKD because increased bleeding and thrombotic risks coexist paradoxically among this population. The morbidity and modality of coagulation disorders vary across CKD stages; patients with advanced CKD (adv‐CKD, stages 4–5) are particularly susceptible to bleeding events.2.Ocak G. Rookmaaker M.B. Algra A. et al.Chronic kidney disease and bleeding risk in patients at high cardiovascular risk: a cohort study.J Thromb Haemost. 2018; 16: 65-73Abstract Full Text Full Text PDF PubMed Scopus (53) Google Scholar, 3.Abdelmaguid A. Roberts L.N. Tugores L. et al.Evaluation of novel coagulation and platelet function assays in patients with chronic kidney disease.J Thromb Haemost. 2022; 20: 845-856Abstract Full Text Full Text PDF PubMed Scopus (3) Google Scholar, 4.Molnar A.O. Bota S.E. Garg A.X. et al.The risk of major hemorrhage with CKD.J Am Soc Nephrol. 2016; 27: 2825-2832Crossref PubMed Scopus (75) Google Scholar Coagulation disorders in patients with CKD seem to have a complex etiology involving platelet dysfunction, endothelial abnormalities, and an altered coagulation cascade and fibrinolysis. Platelets are centrally positioned, conflicting with their hemostatic functions within the CKD population.5.Baaten C. Sternkopf M. Henning T. Marx N. Jankowski J. Noels H. Platelet function in CKD: a systematic review and meta‐analysis.J Am Soc Nephrol. 2021; 32: 1583-1598Crossref Scopus (17) Google Scholar In addition to platelet function, platelet count is equally important for hemostasis maintenance. Mild platelet count reductions have been documented in patients with adv‐CKD; however, the underlying mechanism and its pathological significance have not been previously defined. CKD is best characterized by the accumulation of large amounts of uremic toxins in the circulation, which creates a uremic milieu. Uremic toxins are well known for their pro‐oxidative and pro‐inflammatory properties and are difficult to eliminate through conventional dialysis. Thus, the viability and/or function of the cell populations involved in hemostasis, including platelets and endothelial cells, which are vulnerable to oxidative and inflammatory insults, are disturbed by the constant uremic‐toxin exposure. The circulating platelet count is principally determined from the equilibrium between their generation from bone marrow megakaryocytes (thrombopoiesis) and their clearance. Platelet clearance rate is determined by the lifespan of the circulating platelets, which is 7–10 days for humans and 3–5 days for mice.6.Quach M.E. Chen W. Li R. Mechanisms of platelet clearance and translation to improve platelet storage.Blood. 2018; 131: 1512-1521Crossref PubMed Scopus (118) Google Scholar In this issue of JTH, Lan et al. used a multipronged approach to examine the impact of adv‐CKD on thrombopoiesis and platelet lifespan using platelets from patients with adv‐CKD and an adv‐CKD mouse model. The authors observed an increased megakaryocyte generation in the primary human hematopoietic stem and progenitor cells cultured with serums from adv‐CKD patients as well as in the bone marrow of adv‐CKD mice. Additionally, they presented convincing data on the adv‐CKD‐induced shortening of platelet lifespan, as reflected by the enhanced platelet clearance in patients and mice with adv‐CKD, which cannot be abrogated when these mice platelets are adoptively transferred to their control littermates. Therefore, they concluded that platelet‐autonomous, irreversible shortening of platelet life span accounts for platelet count decline in adv‐CKD. The Klotho protein, which is primarily expressed and secreted by the kidneys (~80%), is well known for its antioxidative and antiaging actions.7.Kuro O.M. The Klotho proteins in health and disease.Nat Rev Nephrol. 2019; 15: 27-44Crossref PubMed Scopus (257) Google Scholar Klotho deficiency is characteristic of CKD and is associated with its progression. Based on a cohort study, the authors observed that the serum Klotho levels positively correlated with platelet counts in patients with CKD. They hypothesized that Klotho may extrinsically affect platelet lifespan because of its absence in megakaryocytes or platelets. Using ex vivo and in vivo experiments, they showed that soluble Klotho treatment relieved adv‐CKD‐induced platelet‐lifespan shortening without a noticeable influence on the homeostatic platelet lifespan. Given the primary renal origin of circulating Klotho, the authors concluded that renal Klotho preserved platelet lifespan in adv‐CKD. This Klotho function is exciting because this is the first report to show that platelet lifespan can be regulated in an interorgan manner by a long‐range factor. From a molecular perspective, the authors demonstrated that this effect is mediated through the platelet Bcl‐xL downregulation, which is attributed to its enhanced ubiquitination and proteasomal degradation. Furthermore, they were the first to identify that ubiquitin‐conjugating enzyme E2O (UBE2O) is the primary ubiquitin ligase responsible for adv‐CKD‐induced Bcl‐xL ubiquitination and demonstrated that the overproduction of reactive oxygen species is induced by the pro‐oxidative adv‐CKD milieu and subsequent activation of the p38 mitogen‐activated protein kinase‐phosphorylated Bcl‐xL, to facilitate its recognition by UBE2O. However, the anti‐oxidative Klotho scavenges the platelet reactive oxygen species and offsets the p38mitogen‐activated protein kinas/UBE2O axis‐mediated Bcl‐xL downregulation to safeguard platelet lifespan in adv‐CKD. These findings substantially advance our understanding of the intrinsic and extrinsic regulatory mechanisms of platelet lifespan. The CKD milieu is very intricate, varying among individuals with CKD. Multiple cellular and molecular circulating Klotho targets exist, including hepatocytes and macrophages, which mediate platelet clearance. The culprit(s) of the CKD milieu responsible for oxidative stress in the platelets and the genuine circulating‐Klotho target(s) remain unclear. Additionally, Klotho can ameliorate kidney injuries and/or enhance residual renal function; therefore, the rescue effect of soluble Klotho on platelet lifespan may be overestimated in vivo. Overall, fully deciphering the interactions between the kidneys and platelets requires further research. Lan et al.8.Daugirdas J.T. Bernardo A.A. Hemodialysis effect on platelet count and function and hemodialysis‐associated thrombocytopenia.Kidney Int. 2012; 82: 147-157Abstract Full Text Full Text PDF PubMed Scopus (127) Google Scholar provided valuable novel information on the cellular and molecular mechanisms underlying platelet count decline in adv‐CKD and promising interventional measures for their management. Although platelet count decline is mild in adv‐CKD, it increases the risk of bleeding in chronic dialysis, which accelerates platelet clearance and potentially leads to thrombocytopenia, and in antithrombotic therapies, which are frequently used for CKD treatment.9.Polzin A. Dannenberg L. Sansone R. et al.Antiplatelet effects of aspirin in chronic kidney disease patients.J Thromb Haemost. 2016; 14: 375-380Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar These results, combined with the previous finding that renal Klotho counteracts CKD‐induced platelet hyperreactivity,10.Yang K. Du C. Wang X. et al.Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease‐associated thrombosis in mice.Blood. 2017; 129: 2667-2679Crossref PubMed Scopus (87) Google Scholar provide insight into the pathogenesis of platelet pathologies across the CKD spectrum and coexistence of increased bleeding and thrombotic risks in CKD, and offer potential prophylactic and therapeutic targets for platelet pathologies with no currently specific interventional measures for this population. Furthermore, chronic diseases and aging seem to be associated with platelet disorders, which contribute to mortality in these populations. Studies by this group provide a good paradigm for understanding and managing platelet pathologies in these scenarios. The author declare no conflicts of interest.